Anterix Officer's Sale Amended: $10M Disclosed, Up from $7.5M
ATEX has more than doubled off its 52-week low of $17.58.
Summary
Anterix officer Christopher Guttman-McCabe's June 15 stock sale was larger than first reported: an amended filing shows he sold $10.04 million worth of shares, up from $7.5 million.
Key Events · Ownership and Investor Activity · ATEX
-
Officer Sale Amended to $10M
Form 4/A reveals Christopher Guttman-McCabe sold 122,852 shares for $10,042,744 on June 15, 2026, up from the originally reported $7.5 million due to a clerical error.
-
Additional 31,415 Shares Sold
The amendment corrects the share count, adding 31,415 shares to the previously disclosed sale, a 34% increase in volume.
-
Sale Price Below Current Market
Shares were sold at weighted average prices ranging from $78.73 to $84.40, compared to today's price of $91.53.
-
Insider Distribution Pattern
This sale is part of a broader 90-day insider selling trend at Anterix, with net open-market sales of $10.16 million across five insiders.
Analysis · ATEX · Technology
This Form 4/A corrects a clerical error in the original June 17 filing, revealing that Chief Regulatory & Communications Officer Christopher Guttman-McCabe sold 31,415 more shares than initially reported. The total sale value rises from approximately $7.5 million to $10.04 million, a 33% increase. The sale occurred on June 15 at prices between $78.73 and $84.40, well below today's $91.53. The amendment does not change the nature of the transaction—an open-market sale by a non-CEO officer—but the larger size makes it more significant for investors tracking insider distribution.
At the time of this filing, ATEX was trading at $91.53 on NASDAQ in the Technology sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $17.58 to $113.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.